Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study

Anders Jørgensen; Ulla Benedichte Søsted Knorr; Mia Greisen Soendergaard; Jens Lykkesfeldt; Anders Fink-Jensen; Henrik Enghusen Poulsen; Martin Balslev Jørgensen; Niels Vidiendal Olsen; Jonatan Myrup Staalsø

doi:10.1186/s12888-015-0455-4

Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study

Anders Jørgensen, Ulla Benedichte Søsted Knorr, Mia Greisen Soendergaard, Jens Lykkesfeldt, Anders Fink-Jensen, Henrik Enghusen Poulsen, Martin Balslev Jørgensen, Niels Vidiendal Olsen, Jonatan Myrup Staalsø

8 Citations (Scopus)

108 Downloads (Pure)

Abstract

BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.

METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.

RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.

CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

Original language	English
Article number	67
Journal	B M C Psychiatry
Volume	15
Number of pages	8
ISSN	1471-244X
DOIs	https://doi.org/10.1186/s12888-015-0455-4
Publication status	Published - 3 Apr 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12888-015-0455-4Licence: CC BY

Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychoticsFinal published version, 418 KBLicence: CC0
s12888-015-0455-4Final published version, 426 KBLicence: CC BY

Cite this

Jørgensen, A., Knorr, U. B. S., Soendergaard, M. G., Lykkesfeldt, J., Fink-Jensen, A., Poulsen, H. E., Jørgensen, M. B., Olsen, N. V., & Staalsø, J. M. (2015). Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study. B M C Psychiatry, 15, Article 67. https://doi.org/10.1186/s12888-015-0455-4

@article{36deab6abd7c456d8e3b20db22e59b34,

title = "Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study",

abstract = "BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.",

author = "Anders J{\o}rgensen and Knorr, {Ulla Benedichte S{\o}sted} and Soendergaard, {Mia Greisen} and Jens Lykkesfeldt and Anders Fink-Jensen and Poulsen, {Henrik Enghusen} and J{\o}rgensen, {Martin Balslev} and Olsen, {Niels Vidiendal} and Staals{\o}, {Jonatan Myrup}",

year = "2015",

month = apr,

day = "3",

doi = "10.1186/s12888-015-0455-4",

language = "English",

volume = "15",

journal = "B M C Psychiatry",

issn = "1471-244X",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics

T2 - a case-control study

AU - Jørgensen, Anders

AU - Knorr, Ulla Benedichte Søsted

AU - Soendergaard, Mia Greisen

AU - Lykkesfeldt, Jens

AU - Fink-Jensen, Anders

AU - Poulsen, Henrik Enghusen

AU - Jørgensen, Martin Balslev

AU - Olsen, Niels Vidiendal

AU - Staalsø, Jonatan Myrup

PY - 2015/4/3

Y1 - 2015/4/3

N2 - BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

AB - BACKGROUND: Schizophrenia is associated with increased cardiovascular morbidity and mortality. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of the nitric oxide synthase, and the L-arginine:ADMA ratio are markers of endothelial dysfunction that predict mortality and adverse outcome in a range of cardiovascular disorders. Increased ADMA levels may also lead to increased oxidative stress. We hypothesized that ADMA and the L-arginine:ADMA ratio are increased in somatically healthy schizophrenia patients treated with atypical antipsychotics (AAP), and that the ADMA and the L-arginine: ADMA ratio are positively correlated to measures of oxidative stress.METHODS: We included 40 schizophrenia patients treated with AAP, but without somatic disease or drug abuse, and 40 healthy controls. Plasma concentrations of ADMA and L-arginine were determined by high-performance liquid chromatography. Data were related to markers of systemic oxidative stress on DNA, RNA and lipids, as well as measures of medication load, duration of disease and current symptomatology.RESULTS: Plasma ADMA and the L-arginine:ADMA ratio did not differ between schizophrenia patients and controls. Furthermore, ADMA and the L-arginine:ADMA ratio showed no correlations with oxidative stress markers, medication load, or Positive and Negative Syndrome Scale scores.CONCLUSIONS: Schizophrenia and treatment with AAP was not associated with increased levels of plasma ADMA or the L-arginine:ADMA ratio. Furthermore, plasma levels of ADMA were not associated with levels of systemic oxidative stress in vivo.

U2 - 10.1186/s12888-015-0455-4

DO - 10.1186/s12888-015-0455-4

M3 - Journal article

C2 - 25880260

SN - 1471-244X

VL - 15

JO - B M C Psychiatry

JF - B M C Psychiatry

M1 - 67

ER -

Asymmetric dimethylarginine in somatically healthy schizophrenia patients treated with atypical antipsychotics: a case-control study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this